We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Liver Biomarkers Tied to Glycemic Control in Diabetes

By Labmedica International staff writers
Posted on 10 Oct 2019
Print article
Image: Abnormal serum hepatic enzymes and lipid levels are associated with glycemic control in patients with type 2 diabetes mellitus (Photo courtesy of SRL Diagnostics).
Image: Abnormal serum hepatic enzymes and lipid levels are associated with glycemic control in patients with type 2 diabetes mellitus (Photo courtesy of SRL Diagnostics).
As liver biomarkers serve as an effective indicator of liver injury in patients whom liver functions are somewhat above average. The abnormality of these markers acts as a worrying sign to the liver function.

Since type 2 diabetes can negatively affect the liver via insulin resistance, these biomarkers maybe linked with the severity of the disease. The association between abnormal hepatic enzyme, lipid levels and glycemic control in patients with type 2 Diabetes Mellitus (T2D) has been assessed.

Clinical scientists from the Ajman University (Ajman, United Arab Emirates) determined whether a relationship exists between abnormal serum hepatic enzymes, lipid levels, and glycemic control in T2D, and conducted a cross-sectional study of 453 patients with T2D (mean age, 54.47 years) from a private healthcare center. They collected sociodemographic, clinical, and laboratory data for each patient from medical records.

The investigators found that of the total population, 80.8% had abnormal levels of one of the tested hepatic enzymes (alanine transaminase [ALT], aspartate transaminase [AST], and albumin), 6.4% had two abnormal parameters, and 2.4% had more than two abnormal parameters. On an individual level, 13.9% had abnormal ALT levels, 3.8% had abnormal AST levels, and 84.5% had abnormal albumin levels. There were no significant differences in abnormal serum hepatic enzymes between men and women.

The team used statistical modeling, and found that all three mean hepatic enzyme levels were jointly and significantly associated with poorly controlled T2D (hemoglobin A1c [HbA1c] ≥7%): an albumin increase of 1 g/dL yielded a 52.7% decrease in risk for poor glycemic control, and an ALT or AST increase of 10 U/L yielded a 36% and 53% increase for HbA1c ≥7%. Furthermore, lipid profiles were also significantly associated with abnormal hepatic levels.

Odds of having abnormal ALT were significantly higher with incremental increases in body mass index, HbA1c, triglycerides, and total cholesterol levels. Odds of having abnormal AST were significantly higher with increases in HbA1c and lower with increases in total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels. Odds of having abnormal hepatic albumin correlated to increases in body mass index, while increases in high-density lipoprotein cholesterol and triglyceride levels were associated with lower odds of having abnormal albumin.

The authors concluded that they had demonstrated that high ALT is characteristic of patients with T2D, pointing to the fact that the development of hepatic anomalies with poor glycemic control attendants could indicate unfavorable evolution of T2D. The study was available online since August 31, 2019, in the journal Obesity Medicine.

Related Links:
Ajman University


Print article

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.